Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palovarotene for FOP Flare-ups Extension
NCT02521792Phase 2Terminated
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Dec 2015
- Primary completion
- Aug 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palovarotene in fibrodysplasia ossificans progressiva (FOP), sponsored by Clementia Pharmaceuticals Inc. Primary endpoint: Treatment-emergent Adverse Events. Started Dec 2015; status: terminated.
02
Drugs
palovarotene
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT02521792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521792.